Navigation Links
SLE in Medical Technology

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

...at emerged in the serologically active subgroup of sle patients at Week 52 in our Phase 2 trial," said Da...significance. BENLYSTA also significantly reduced sle disease activity versus placebo based on a number ...n collaboration with GSK and leading international sle experts, and the program is being conducted under ...

Lupus Foundation of America Fosters the Next Generation of Lupus Researchers by Awarding Gina M. Finzi Memorial Student Summer Fellowships to Five Students

... Tarak Trivedi, The University of Chicago (Chicago, IL) "Analysis of sle Clinical Characteristics Using sle Susceptibility Genes" The Foundation's national research program, Bri...

Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference

... 2010, and we believe it could become the first new drug approved by the FDA for the treatment of lupus in 50 years," said Mr. Watkins. "Patients with sle need new treatment options; we hope to be able to help meet that need with LymphoStat-B." Key goals for LymphoStat-B in 2009: R...

Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus

...lled trials evaluating the efficacy and safety of epratuzumab for the treatment of severe BILAG A and/or moderate BILAG B in two or more organ systems sle flare, respectively. Both trials terminated early due to interruptions in medication supply. Among both trials, 90 patients were randomized to receive...

Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial

...ort of a potential Biologics License Application (BLA). HGS designed the belimumab Phase 3 program in collaboration with GSK and leading international sle experts. "The belimumab clinical investigators have done a tremendous job in completing the randomization and initial dosing of BLISS-52 and BLISS-7...

Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus

...uman monoclonal antibody targeting interferon-alpha. Published data indicate that levels of interferon-alpha are elevated in many patients with active sle and other autoimmune disorders, and may be associated with disease activity. Preclinical data from animal models suggest that MEDI-545 may suppress th...

Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus

...play an important role in the treatment of SLE." sle is a chronic, life-threatening autoimmune disease....cally active SLE, we saw significant reductions in sle disease activity versus placebo based on multiple ...epresent a significant advance in the treatment of sle if Phase 2 results are confirmed in the Phase 3 tr...

Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives

...tific meetings at earlier time points, including a significant reduction in sle disease activity as measured by the response rate chosen as the primary eff... a protocol design informed by prior randomized data. Today's therapy for sle patients involves a variety of immunosuppressive and cytotoxic agents, with...

Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus

...al of Rituxan (rituximab) for the treatment of lupus. The study did not meet its primary or secondary endpoints of clinically reducing the severity of sle (systemic lupus erythematosus) in people with moderate disease. The findings are initial results from a Phase II/III study conducted by Genentech,...

Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials

...he results of previous studies suggest that belimumab significantly reduced sle disease activity in serologically active patients," said Professor Sandra V...oStat-B Phase 3 program in collaboration with GSK and leading international sle experts. "A total of nearly 1700 patients worldwide will be enrolled and ...

Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus

... observed for LymphoStat-B in serologically active sle patients at 52 weeks appears to be sustained throu... with active SLE, we saw significant reductions in sle disease activity versus placebo as measured by the...rsus placebo in patients with serologically active sle across multiple clinical measures, exhibited clini...

Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus

...TLRs 7, 8 and 9 and inhibit disease development in sle and other autoimmune disorders. CPG 52364 has been...medical need." CPG 52364's Mechanism of Action in sle The defining characteristic of sle is the production of autoantibodies, abnormal anti...

La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial

...0 (US) or (617) 801-6888 (International). The passcode for the replay is 33112152. These data will be presented at the 8th International Congress on sle in Shanghai in May 2007. Phase 3 Study Design The Phase 3 study is designed to assess the ability of Riquent treatment to prevent or delay the tim...

Positive Clinical Data for TASQ - Active Biotech's Novel Treatment of Prostate Cancer

...n being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for sle and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics. Ac...

Active Biotech's I-3D Micro-dosing Clinical Trial Concluded

...n being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for sle and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics. Ac...

La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial

...from that seen in previous studies where 100 mg of Riquent was the treatment dose. These data will be presented at the 8th International Congress on sle in Shanghai in May 2007. Phase 3 Study Design The Phase 3 study is designed to assess the ability of Riquent treatment to prevent or delay the tim...

Laquinimod, a Novel Oral Compound, Showed Significant Reduction in Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)

... being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for sle and RhuDex(R) for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics Interna...

ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia

...s such as systemic lupus erythematosus (SLE). Current data indicates that levels of BLyS and APRIL are elevated in patients with rheumatoid arthritis, sle and B-cell malignancies. Atacicept has been shown to affect several stages of B-cell development and may inhibit the survival of cells responsible for...

Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus

...lyn. "At Week 52, we saw significant reductions in sle disease activity as measured by the SELENA SLEDAI ...ation of LymphoStat-B as a potential treatment for sle in the Phase 3 trials that are now underway," she ...ndard of care. A total of 449 patients with active sle were randomized to receive one of three different ...

New Positive Pre-clinical Data for Active Biotech's RA Project I-3D

... being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for sle and RhuDex® for RA. In addition, the preclinical development of the I-3D project is conducted in cooperation with Chelsea Therapeutics Internation...

Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation

...clinical development of 57-57 for the treatment of sle and show the possibility to reduce the use of ster...Sven Andréasson President & CEO About sle and 57-57 Systematic Lupus Erythematosus (SLE) is ...in the US and Europe. The market potential for the sle indication is estimated at approximately USD 6 bil...

Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis

...on. Aspreva estimates that there are about 600,000 diagnosed lupus nephritis patients worldwide. There have been no new approved treatment options for sle or lupus nephritis in the United States in over forty years. Current induction treatments involve the off-label use of existing cancer drugs such as c...

Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease

...al thrombosis) in patients with autoimmune diseases such as systemic lupus erythematosus (SLE) and anti-phospholipid syndrome. The study looked at 113 sle patients (94 with secondary anti-phospholipid syndrome and 19 without) and concluded the measurement of anti-AtherOx is significantly better than conv...
Other Tags
(Date:7/2/2015)... , June 25, 2015 ... of the "Next Generation Biometrics Market by Application, ... report to their offering. The next ... by 2020, at a CAGR of 17.9% between 2015 ... leading application for the market. Safran SA ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/25/2015)... June 25, 2015 According ... Type (Swipe & Area), Technology, Material (Optical Prism, ... Commercial Security & Others) & Geography - Global ... the said market is expected to reach $14,500.07 ... Browse 76 market Tables and ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
(Date:7/30/2015)... California (PRWEB) , ... July 30, 2015 , ... Dale ... the United States, will speak at the International Cannabis Professionals Expo held at the ... , The International Cannabis Professionals Expo is the largest medical cannabis ...
(Date:7/30/2015)... ... , ... Committed to helping the next generation succeed - Mercy College is ... the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative issues a call to ... support they need to think more broadly about their future. Building on what works ...
(Date:7/30/2015)... ... 30, 2015 , ... OSF Healthcare System has been recognized as ... Survey conducted by Hospitals & Health Networks. This marks the fourth consecutive year for ... The Sisters of the Third Order of St. Francis . , Health data security ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca ... on the go. With no water needed, the refreshing berry-flavored tablets are the ... to get the natural ingredients that may help with body detoxification, protection and ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... scientific program at ATA’s 21st Annual Meeting and Tradeshow focused exclusively on telemedicine, ... than 300 cutting-edge health care technology vendors, will take place May 14-17, 2016 ...
Breaking Medicine News(10 mins):Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3
Other Contents